The inherent resistance to ICIs in HR+ breast cancer is attributed to the low tumor mutational burden, low percentage of stromal tumor-infiltrating lymphocytes (sTIL), and low PD-L1 expression (7–9). This evidence concerns the gene CD274 and neoplasm.